Information Provided By: 
Fly News Breaks for August 10, 2016
MYGN
Aug 10, 2016 | 05:44 EDT
Piper Jaffray analyst William Quirk downgraded Myriad Genetics to Neutral citing share losses in the Hereditary Cancer business and the company's weaker than expected guidance. Reimbursement risk combined with sales force losses will put pressure on the organization for the near term, Quirk tells investors in a post-earnings research note. He cut his price target for the shares to $22 from $47. Barclays this morning also downgraded Myriad Genetics.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
